Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INOTUZUMAB OZOGAMICIN for Acute lymphocytic leukaemia recurrent: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 170 adverse event reports in the FDA FAERS database where INOTUZUMAB OZOGAMICIN was used for Acute lymphocytic leukaemia recurrent.

Most Reported Side Effects for INOTUZUMAB OZOGAMICIN

Side Effect Reports % Deaths Hosp.
Death 253 10.9% 253 14
Febrile neutropenia 230 9.9% 36 174
Venoocclusive liver disease 229 9.9% 114 72
Neoplasm progression 158 6.8% 104 26
Pyrexia 151 6.5% 34 109
Off label use 146 6.3% 63 38
Sepsis 119 5.1% 75 55
Venoocclusive disease 109 4.7% 44 37
Thrombocytopenia 108 4.7% 23 47
Platelet count decreased 107 4.6% 31 66
Drug ineffective 92 4.0% 39 27
Neutropenia 90 3.9% 33 33
Cytokine release syndrome 84 3.6% 24 38
Pneumonia 83 3.6% 39 52
Blood bilirubin increased 77 3.3% 23 36

Other Indications for INOTUZUMAB OZOGAMICIN

Acute lymphocytic leukaemia (948) B-cell type acute leukaemia (210) B precursor type acute leukaemia (104) Product used for unknown indication (100) Diffuse large b-cell lymphoma (88) Non-hodgkin's lymphoma (56) Acute lymphocytic leukaemia refractory (31) Precursor b-lymphoblastic lymphoma (19) Acute leukaemia (15) Leukaemia (14)

Other Drugs Used for Acute lymphocytic leukaemia recurrent

BLINATUMOMAB (783) VINCRISTINE (339) METHOTREXATE (318) DEXAMETHASONE (266) CYCLOPHOSPHAMIDE (243) CYTARABINE (233) TISAGENLECLEUCEL (225) PONATINIB (195) PEGASPARGASE (172) DOXORUBICIN (146)

Related Pages

INOTUZUMAB OZOGAMICIN Full Profile All Acute lymphocytic leukaemia recurrent Drugs INOTUZUMAB OZOGAMICIN Demographics INOTUZUMAB OZOGAMICIN Timeline